⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Datroway ® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
businesswire.com
AZN
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
businesswire.com
AZN
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
businesswire.com
AZN
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
globenewswire.com
MRK
SNY
AZN
REGN
JNJ
CABA
Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight
prnewswire.com
NVO
BMY
JNJ
AMGN
REGN
SNY
PFE
AZN
LLY
NVS
Idiopathic Pulmonary Fibrosis Market Dynamics, Opportunity Analysis and Forecast Report 2026-2035: Therapeutic Landscape is Anchored by Two Key Products - Esbriet (Pirfenidone), and Ofev
globenewswire.com
BIIB
AZN
FGEN
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic
prnewswire.com
ABBV
AZN
BMY
LLY
NVO
Decades of Neglect Leaves Millions of People with COPD at Risk--National COPD Leaders Call for Urgent Policy Action USA - English USA - English USA - English
prnewswire.com
AZN
SNY
REGN
GSK
Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 with Increasing Adoption of Targeted Radiotherapy | DelveInsight
prnewswire.com
LH
TH
GEHC
EL
AZN
AMGN
PFE
MRK
BMY
REGN
GILD
ABBV
SNY
XRAY
BRKR